DOI QR코드

DOI QR Code

Prevalence and Genotype Distribution of Human Papillomavirus among Women from Henan, China

  • Wang, Xiao-Chuan (Department of Clinical Laboratory, No. 150 Central Hospital of PLA) ;
  • Sun, Liang-Qi (Department of Clinical Laboratory, No. 150 Central Hospital of PLA) ;
  • Ma, Li (Department of Clinical Laboratory, No. 150 Central Hospital of PLA) ;
  • Li, Hua-Xin (Department of Clinical Laboratory, No. 150 Central Hospital of PLA) ;
  • Wang, Xiu-Li (Department of Clinical Laboratory, No. 150 Central Hospital of PLA) ;
  • Wang, Xin (Department of Obstetrics and Gynecology, No. 150 Central Hospital of PLA) ;
  • Yun, Tian (Department of pathology, No. 150 Central Hospital of PLA) ;
  • Meng, Nian-Long (Department of pathology, No. 150 Central Hospital of PLA) ;
  • Lv, Da-Le (Department of Clinical Laboratory, No. 150 Central Hospital of PLA)
  • Published : 2014.09.15

Abstract

Human papillomavirus (HPV) infection has been implicated as a causative of cervical cancer. In the present study, a total of 578 samples from females attending the gynecological outpatient clinic in Henan province, China, were collected and the HPV genotypes were detected by gene chip and flow-through hybridization. Overall, 44.5% (257/578) females were found to be HPV DNA positive, and the high risk HPV (HR-HPV) rate was 35.1% (203/578). The first peak of HR-HPV infection appeared in the >60 year-old group (55.0%), and the second was within the 51-55 year-old group (50.0%) (${\chi}^2$=19.497, p<0.05). HPV 16 was the most prevalent genotype (9.2%), followed by HPV 52 (7.8%), HPV 6 (6.9%), HPV 11 (5.9%) and HPV 42 (5.0%). The single type HPV infection was 30.4%, with the five majority prevalent genotype HPV 16 (16.5%), HPV 52 (14.3%), HPV 6 (12.6%), HPV 42 (8.6%), HPV 31 (5.1%). The multiple-type HPV infections were 14.0%, and HPV 16 was the most prevalent type (29.6%), followed by HPV 52 (24.7%), HPV 6 (22.2%), HPV 11 (22.2%), HPV 42 (17.3%) and HPV 39 (17.3%).

Keywords

Human papillomavirus;prevalence;genotype;Henan, China

References

  1. Althoff KN, Paul P, Burke AE, et al (2009). Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health, 18, 1341-6. https://doi.org/10.1089/jwh.2008.1223
  2. Castle PE, Schiffman M, Herrero R, et al (2005). A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis, 191, 1808-16. https://doi.org/10.1086/428779
  3. Dalstein V, Riethmuller D, Pretet JL, et al (2003). Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer, 106, 396-403. https://doi.org/10.1002/ijc.11222
  4. Datta P, Bhatla N, Pandey RM, et al (2012). Type-specific incidence and persistence of HPV infection among young women: a prospective study in North India. Asian Pac J Cancer Prev, 13, 1019-24. https://doi.org/10.7314/APJCP.2012.13.3.1019
  5. Dickson EL, Vogel RI, Geller MA, et al (2014). Cervical cytology and multiple type HPV infection: A study of 8182 women ages 31-65. Gynecol Oncol, 133, 405-8. https://doi.org/10.1016/j.ygyno.2014.03.552
  6. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  7. Goodman MT, Shvetsov YB, McDuffie K, et al (2008). Prevalence, acquisition and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res, 68, 8813-24. https://doi.org/10.1158/0008-5472.CAN-08-1380
  8. Hou R, Xu CY, Zhang SW, et al (2012). Distribution of human papillomavirus genotype and cervical neoplasia among women with abnormal cytology in Beijing, China. Int J Gynecol Obstet, 119, 257-61. https://doi.org/10.1016/j.ijgo.2012.07.011
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  10. Levin CE, Sellors J, Shi JF, et al (2010). Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 127, 1404-11. https://doi.org/10.1002/ijc.25150
  11. Li J, Huang R, Schmidt JE, et al (2013). Epidemiological features of human papillomavirus (HPV) infection among women living in Mainland China. Asian Pac J Cancer Prev, 14, 4015-23. https://doi.org/10.7314/APJCP.2013.14.7.4015
  12. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27. https://doi.org/10.1056/NEJMoa021641
  13. Rai AK, Das D, Kataki AC, et al (2014). Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India. Asian Pac J Cancer Prev, 15, 861-5. https://doi.org/10.7314/APJCP.2014.15.2.861
  14. Schlecht NF, Kulaga S, Robitaille J, et al (2001). Persistent human papillomavirus infection as a predictor of cervical intraepitelisal neoplasia. JAMA, 286, 3106-14. https://doi.org/10.1001/jama.286.24.3106
  15. Wang YY, Li L, Wei S, Peng J, et al (2013). Human papillomavirus (HPV) infection in women participating in cervical cancer screening from 2006 to 2010 in Shenzhen City, South China. Asian Pac J Cancer Prev, 14, 7483-7. https://doi.org/10.7314/APJCP.2013.14.12.7483
  16. Wheeler CM, Hunt WC, Joste NE, et al (2009). Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst, 101, 475-87. https://doi.org/10.1093/jnci/djn510
  17. Xue YZ, Zhang WY, Chen M, et al (2009). "U'' shape of agespecific prevalence of high-risk human papillomavirus infection in women attending hospitals in Shanghai, China. Eur J Obstet Gynecol Reprod Biol, 145, 214-8. https://doi.org/10.1016/j.ejogrb.2009.05.020
  18. Ye J, Cheng XD, Chen XJ, et al (2010). Prevalence and risk profile of ervical human papillomavirus infection in Zhejiang Province, southeast China a population-based study. Virol J, 7, 66. https://doi.org/10.1186/1743-422X-7-66
  19. Zhao FH, Lin MJ, Chen F, et al (2010). Performance of highrisk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol, 11, 1160-71. https://doi.org/10.1016/S1470-2045(10)70256-4

Cited by

  1. Evaluation of Several Screening Approaches for Detection of Cervical Lesions in Rural Shandong, China vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1907
  2. Prevalence and genotype distribution of human papillomavirus: implications for cancer screening and vaccination in Henan province, China vol.49, pp.2, 2016, https://doi.org/10.1590/0037-8682-0192-2015
  3. Prevalence of High-Risk Genotypes of Human Papillomavirus: Women Diagnosed with Premalignant and Malignant Pap Smear Tests in Southern Ecuador vol.2017, pp.1098-0997, 2017, https://doi.org/10.1155/2017/8572065
  4. Epidemiology of Humanpapilloma virus infection among women in Fujian, China vol.18, pp.1, 2018, https://doi.org/10.1186/s12889-017-4651-7
  5. Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology vol.11, pp.1, 2019, https://doi.org/10.3390/v11010063
  6. Apparent diffusion coefficients are closely related with high-risk human papilloma virus infection in cervical squamous cell carcinoma patients pp.1600-0455, 2019, https://doi.org/10.1177/0284185119828202